ArticleJournal for immunotherapy of cancer2023

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.

Emily Maria Ploeg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.